ABT

114.23

1.61% 1.81

Handel nachbörslich: 114.23

Abbott Laboratories (ABT)

Überblick Nachrichten Preisverlauf Optionskette Financials Forum Prognose Aktiensplit Dividendenhistorie

Schlusskurs vom Vortag:

$112.42

Offen:

$112.64

24-Stunden-Volumen:

9.92M

Relative Volume:

2.11

Marktkapitalisierung:

$198.13B

Einnahmen:

$41.22B

Nettoeinkommen (Verlust:

$5.77B

KGV:

38.85

EPS:

2.94

Netto-Cashflow:

$6.49B

1W Leistung:

+0.75%

1M Leistung:

-1.47%

6M Leistung:

+7.19%

1J Leistung:

+6.36%

1-Tages-Spanne:

$112.52

$115.11

1-Wochen-Bereich:

$111.28

$115.11

52-Wochen-Spanne:

$99.71

$121.64

Abbott Laboratories Stock (ABT) Company Profile

Firmenname

Abbott Laboratories

Sektor

Healthcare (1176)

Branche

Medical Devices (148)

Telefon

(224) 667-6100

Adresse

100 ABBOTT PARK ROAD, ABBOTT PARK, IL

Mitarbeiter

114,000

Twitter

@AbbottNews

Nächster Verdiensttermin

2024-10-16

Neueste SEC-Einreichungen

ABT's Discussions on Twitter

Vergleichen Sie ABT mit anderen Aktien

Aktien	Preis	Marktkapitalisierung	Umsatz	Nettogewinn	Free Cashflow	ENV
ABT Abbott Laboratories	114.23	198.13B	41.22B	5.77B	6.49B	3.29
SYK Stryker Corp	364.60	138.99B	21.97B	3.59B	3.21B	9.33
BSX Boston Scientific Corp	88.95	131.10B	15.91B	1.79B	1.89B	1.21
MDT Medtronic Plc	81.03	103.90B	33.00B	4.29B	5.50B	3.27
EW Edwards Lifesciences Corp	74.81	44.12B	6.60B	4.16B	490.10M	6.93

Abbott Laboratories Stock (ABT) Upgrades & Downgrades

Datum	Aktion	Analytiker	Ratingänderung
2024-10-08	Eingeleitet	Oppenheimer	Outperform
2024-09-19	Eingeleitet	Piper Sandler	Overweight
2024-07-30	Herabstufung	Edward Jones	Buy → Hold
2024-05-30	Eingeleitet	Goldman	Buy
2023-07-21	Hochstufung	Wolfe Research	Underperform → Peer Perform
2023-05-30	Herabstufung	Morgan Stanley	Overweight → Equal-Weight
2023-04-20	Bestätigt	Barclays	Overweight
2023-04-20	Bestätigt	Bernstein	Outperform
2023-04-20	Bestätigt	JP Morgan	Overweight
2023-04-20	Bestätigt	Raymond James	Outperform
2023-04-20	Bestätigt	UBS	Buy
2023-04-20	Bestätigt	Wolfe Research	Underperform
2023-03-29	Eingeleitet	UBS	Buy
2022-10-26	Eingeleitet	Mizuho	Neutral
2022-10-18	Eingeleitet	Barclays	Overweight
2022-10-12	Eingeleitet	Jefferies	Hold
2022-07-06	Eingeleitet	Wolfe Research	Underperform
2022-03-02	Fortgesetzt	BofA Securities	Buy
2022-01-27	Bestätigt	Credit Suisse	Outperform
2022-01-27	Bestätigt	Morgan Stanley	Overweight
2022-01-27	Bestätigt	Raymond James	Outperform
2022-01-27	Bestätigt	UBS	Buy
2021-12-10	Eingeleitet	RBC Capital Mkts	Outperform
2021-10-27	Hochstufung	Atlantic Equities	Neutral → Overweight
2021-10-14	Eingeleitet	Redburn	Neutral
2021-05-25	Eingeleitet	Barclays	Overweight
2021-04-15	Eingeleitet	Atlantic Equities	Neutral
2021-01-28	Hochstufung	BTIG Research	Neutral → Buy
2020-09-11	Eingeleitet	Wolfe Research	Outperform
2020-06-01	Herabstufung	Goldman	Neutral → Sell
2020-03-05	Eingeleitet	Citigroup	Buy
2020-02-13	Eingeleitet	Goldman	Neutral
2020-02-06	Fortgesetzt	BTIG Research	Neutral
2020-01-02	Herabstufung	Guggenheim	Buy → Neutral
2019-06-13	Bestätigt	BofA/Merrill	Buy
2019-02-07	Bestätigt	BofA/Merrill	Buy
2019-01-02	Herabstufung	Citigroup	Neutral → Sell
2018-11-30	Hochstufung	Goldman	Neutral → Buy
2018-10-16	Eingeleitet	Barclays	Overweight
2018-06-27	Eingeleitet	Bernstein	Outperform
2018-01-30	Bestätigt	Citigroup	Neutral
2018-01-25	Bestätigt	Stifel	Buy
2018-01-25	Hochstufung	William Blair	Mkt Perform → Outperform
2018-01-03	Eingeleitet	Evercore ISI	Outperform
2018-01-02	Hochstufung	JP Morgan	Neutral → Overweight
2018-01-02	Hochstufung	Morgan Stanley	Equal-Weight → Overweight
2017-10-19	Bestätigt	RBC Capital Mkts	Outperform
2017-10-19	Bestätigt	Stifel	Buy

Alle ansehen

Abbott Laboratories Aktie (ABT) Neueste Nachrichten

04:31 AM

M&T Bank Corp Has $110.42 Million Holdings in Abbott Laboratories (NYSE:ABT) - MarketBeat

04:31 AM

04:27 AM

Abbott Laboratories: A Future-Driven Pharma Brand With A Robust Pipeline - Seeking Alpha

04:27 AM

Dec 20, 2024

Abbott Whistleblower's False Claims Suit is Revived, Narrowed - Bloomberg Law

Dec 20, 2024

Abbott Labs stock target increased, buy rating on strong product lineup - Investing.com

Dec 20, 2024

The Zacks Analyst Blog Highlights Veracyte, Omnicell, Masimo and Abbott Laboratories - Yahoo Finance

Dec 20, 2024

XTX Topco Ltd Sells 31,480 Shares of Abbott Laboratories (NYSE:ABT) - MarketBeat

Dec 20, 2024

Abbott Laboratories (NYSE:ABT) Given Average Rating of "Moderate Buy" by Brokerages - MarketBeat

Dec 20, 2024

Dec 19, 2024

Abbott Laboratories stock outperforms competitors on strong trading day - MarketWatch

Dec 19, 2024

Abbott announces “first-in-world” leadless pacing procedures in left bundle branch area of heart - Cardiac Rhythm News

Dec 19, 2024

Implantable Loop Recorder Market Top Companies StudyAbbott - openPR

Dec 19, 2024

Dec 18, 2024

Syntax Research Inc. Makes New $2.28 Million Investment in Abbott Laboratories (NYSE:ABT) - MarketBeat

Dec 18, 2024

The Smartest Dividend Stocks to Buy With $500 Right Now - The Motley Fool

Dec 18, 2024

Biochips Market Huge Growth in Future Scope 2024-2031 | Abbott - openPR

Dec 18, 2024

Dec 17, 2024

Abbott (ABT) Increases Despite Market Slip: Here's What You Need to Know - Yahoo Finance

Dec 17, 2024

Abbott Laboratories stock underperforms Tuesday when compared to competitors despite daily gains - MarketWatch

Dec 17, 2024

Cardiologists perform world’s first leadless LBBAP procedures with Abbott pacemaker - Cardiovascular Business

Dec 17, 2024

Abbott completes first-in-human leadless left bundle branch area pacing procedures - Mass Device

Dec 17, 2024

Cardiac Biomarkers Market CAGR of 13.3% Size, Current Trends, Future Prospects By 2024-2031 | Abbott - EIN News

Dec 17, 2024

Are Abbott Laboratories' (NYSE:ABT) Fundamentals Good Enough to Warrant Buying Given The Stock's Recent Weakness? - Yahoo Finance

Dec 17, 2024

Abbott Announces First-in-World Leadless Pacing Procedures in the Left Bundle Branch Area of the Heart - The Eastern Progress Online

Dec 17, 2024

Dec 16, 2024